Clinical Trials Browser

Phase 1 × NIH × sapanisertib × Clear all

NCT02503722 2026-04-13

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04250545 2025-11-25

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

NCT02142803 2025-11-13

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1 Completed

83 enrolled 21 charts

GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

NCT02133183 2024-04-04

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Phase 1 Terminated

Glioblastoma, Gliosarcoma